Details of Disease

General Information of Disease (ID: DISECZYI)

• Disease Name: Hepatic fibrosis
• Disease Class: DB93: Hepatic fibrosis/cirrhosis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISECZYI: Hepatic fibrosis
• ICD Code:
  ICD-11: ICD-11: DB93.0
  ICD-10: ICD-10: K74.0
  ICD-9: ICD-9: 709.2
  Expand ICD-11: 'DB93.0
  Expand ICD-10: 'K74.0
  Expand ICD-9: 709.2
• Disease Identifiers:
  MESH ID: D008103
  MedGen ID: 116093
  HPO ID: HP:0001395
  SNOMED CT ID: 62484002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Actimmune	DM3APM9	Approved	NA	[1]
Ademetionine	DMYQDBO	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Epigallocatechin gallate	DMCGWBJ	Phase 3	Small molecular drug	[3]
BMS-986263	DMSRVXO	Phase 2	Small interfering RNA	[4]
Emricasan	DMDCCPC	Phase 2	Small molecular drug	[5]
PX-102	DMWU682	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-13	DMZHIM8	Patented	Small molecular drug	[7]

This Disease is Treated as An Indication in 5 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CWHM-12	DM8YUJT	Preclinical	Small molecular drug	[8]
dioscin	DM5H2W9	Preclinical	Small molecular drug	[9]
GW4064	DMCGEDY	Preclinical	Small molecular drug	[9]
INT-767	DMRJ9P4	Preclinical	Small molecular drug	[10]
VX-166	DMZKY56	Preclinical	Small molecular drug	[9]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GM-CT-02	DMRHPOY	Investigative	NA	[11]
GM-MD-01	DMA50JF	Investigative	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2007
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2013
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7002).
• [4] ClinicalTrials.gov (NCT04267393) Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6508).
• [6] ClinicalTrials.gov (NCT01998659) Single Ascending Oral Dose Phase I Study With Px-102. U.S. National Institutes of Health.
• [7] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [8] Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.
• [9] Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
• [10] Clinical pipeline report, company report or official report of Intercept.
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.